Treatment response and progression to end stage renal disease in adolescents and young adults with lupus nephritis: A follow up study in an Egyptian cohort
Publication date: Available online 10 January 2020Source: The Egyptian RheumatologistAuthor(s): Maryam A. Abdulrahman, Dina E. SallamAbstractBackgroundLupus nephritis (LN) badly affects the outcome in adolescents and young adults with systemic lupus erythematosus (SLE). Many have renal disease at onset and the significance of remission and relapse in adolescents and young adults is poorly evaluated.Aim of workTo outline the clinical and laboratory characteristics of treatment resistance, renal relapse and progression to end-stage renal disease (ESRD) in adolescents and young adults with LN.Patients and methodsEighty-five biopsy-proven LN patients were examined; SLE disease activity and renal damage were evaluated at baseline and followed up at 6 and 12 months. Laboratory and immunology profiles were assessed. Patients were evaluated for predictors of treatment response, renal flares, and renal survival.ResultsThe patients mean age was 15.12 ± 4.53 years. Female/male ratio was 10.5:1. 12.9% had treatment resistance, 87.1% achieved remission: complete (CR 31.8%) and partial (PR 55.2%) within 1st year. 27 (31.8%) developed a relapse within the 1st year (9 after CR and 18 after PR). Nephrotic range proteinuria persisted in 24 (28.2%) patients (13 PR and the 11 non-responders). Baseline hypertension (p = 0.034), persistent nephrotic range proteinuria (
CONCLUSIONS: Not all interventional procedures result in a mortality benefit. Medical therapy alone increases survival in many cardiac diseases. PMID: 32083425 [PubMed - as supplied by publisher]
Authors: Nuotio J, Suvila K, Cheng S, Langén V, Niiranen T Abstract Observational and interventional studies have unequivocally demonstrated that "present", i.e. single-occasion, blood pressure is one of the key determinants of cardiovascular disease risk. Over the past two decades, however, numerous publications have suggested that longitudinal blood pressure data and assessment of long-term blood pressure exposure provide incremental prognostic value over present blood pressure. These studies have used several different indices to quantify the overall exposure to blood pressure, such as time-aver...
Conclusions Surufatinib demonstrated promising efficacy with a tolerable and manageable safety profile for patients with locally advanced or metastatic MTC, RAI-refractory DTC, or locally advanced, unresectable recurrences unable to receive RAI. PMID: 32075524 [PubMed - as supplied by publisher]
The role of PPAR gamma agonists - rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J2 in experimental cyclosporine A hepatotoxicity. J Physiol Pharmacol. 2019 Dec;70(6): Authors: Sikora-Wiorkowska A, Smolen A, Czechowska G, Wiorkowski K, Korolczuk A Abstract Cyclosporine A (CsA) is an immunosuppressive drug used in transplantation and treatment of autoimmune diseases. Experimental studies revealed impairments in liver function and morphology among cyclosporine-treated animals. The aim of the study was to evaluate hepatoprotective activity of peroxisome-proliferator-activated receptors γ (PPA...
Corrigendum to "Association between Serum Matrix Metalloproteinase- (MMP-) 3 Levels and Systemic Lupus Erythematosus: A Meta-Analysis". Dis Markers. 2020;2020:5943216 Authors: Lee JM, Kronbichler A, Park SJ, Kim SH, Han KH, Kang HG, Ha IS, Cheong HI, Kim KH, Kim G, Kim DS, Chae HW, Lee CH, Lee KH, Shin JI Abstract [This corrects the article DOI: 10.1155/2019/9796735.]. PMID: 32082435 [PubMed - in process]
ConclusionsThere are elevated levels of risk for CVD in some athletes, primarily football players. Lifestyle behaviours associated with elite athleticism, particularly football linemen potentially expose players to greater metabolic and CVD risk, which is not completely offset by sport participation.
Authors: Rateb MF, Abdel Motaal H, Shehata M, Anwar M, Tohamy D, Saleh MGA Abstract Purpose: To compare safety and efficacy between a low-cost glaucoma drainage device (GDD), the Aurolab aqueous drainage implant (AADI), and the Baerveldt glaucoma implant (BGI) in refractory childhood glaucoma in Egypt. Methods: This is a retrospective study of patients who received either an AADI or BGI at a tertiary care postgraduate teaching institute. Children aged
Conclusions: Sofosbuvir appears to have no nephrotoxic effects and is safe to treat patients with chronic HCV infection. PMID: 32083035 [PubMed - in process]
In conclusion, our data suggests that progression to kidney disease might not be a major concern in women after preeclampsia within 18 years postpartum.
Publication date: January 2020Source: Pregnancy Hypertension, Volume 19Author(s): Zain Awamleh, Victor K.M. HanAbstractPreeclampsia (PE) and intrauterine growth restriction (IUGR) are pregnancy complications resulting from abnormal placental development. As epigenetic regulators, microRNAs can regulate placental development and contribute to the disease pathophysiology by influencing the expression of genes involved in placental development or disease. Our previous study revealed an increase in miR-210-5p expression in placentae from patients with early-onset pregnancy complications and identified candidate gene targets fo...